Alzheimer’s Symptom in Nose May Precede Memory Loss: Medical Study 2026

Key Points

• Biological changes in the nose and a reduced sense of smell can show up years before memory loss occurs in Alzheimer’s patients.
• Researchers at the German Centre for Neurodegenerative Diseases (DZNE) found that brain immune cells, known as microglia, break down nerve connections between the locus coeruleus and the olfactory bulb.
• Overactive neurons push a membrane molecule called phosphatidylserine to the outside of the cell, which acts as an “eat-me” signal for microglia.
• A study by Duke Health showed that a non-invasive nasal swab can collect living olfactory tissue to spot Alzheimer’s biomarkers with 81 per cent accuracy.
• Catching the disease early through the nose allows doctors to begin treatment with monoclonal amyloid-beta antibodies before severe brain damage develops.

DURHAM (Edinburgh Daily) November 3, 2026 — A series of milestone medical studies published in Nature Communications has established that subtle olfactory dysfunction and distinct cellular changes in the upper nasal cavity can indicate the presence of Alzheimer’s disease long before classic cognitive decline manifests.

Scientists investigating neurodegenerative pathology have confirmed that the loss of smell is not merely a secondary consequence of cognitive decline, but rather an active early mechanism driven by early-stage immune responses inside the olfactory circuit.

As reported by science writer ScienceDaily on behalf of the German Centre for Neurodegenerative Diseases (DZNE), Dr Lars Paeger, a lead scientist at DZNE and Ludwig-Maximilians-Universität (LMU) München, stated that “our study suggests that in early Alzheimer’s disease, changes occur in the nerve fibers linking the locus coeruleus to the olfactory bulb”.

Dr Paeger further detailed the biological signaling mechanism, observing that “these alterations signal to the microglia that affected fibers are defective or superfluous. Consequently, the microglia break them down”.

How do immune cells target nasal neural pathways in early Alzheimer’s?

The research conducted by the DZNE team, led jointly by Dr Lars Paeger and co-author Prof Dr Jochen Herms, revealed that neuronal hyperactivity in early Alzheimer’s alters the outer lipid layer of nerve fibers connecting the brainstem to the smelling center.

Under typical physiological conditions, a structural fatty molecule named phosphatidylserine remains contained on the interior surface of the neuronal cell membrane. However, cellular stress causes phosphatidylserine to relocate to the exterior surface, creating an immunological signal.

As reported in the research documentation, Dr Paeger stated:

“Presence of phosphatidylserine at the outer site of the cell membrane is known to be an ‘eat-me’ signal for microglia. In the olfactory bulb, this is usually associated with a process called synaptic pruning, which serves to remove unnecessary or dysfunctional neuronal connections.”

“This would allow earlier intervention with amyloid-beta antibodies, increasing the probability of a positive response,” added Prof Dr Jochen Herms regarding the clinical therapeutic advantages.

Can a simple nasal swab replace complex brain scans for early diagnosis?

In a complementary scientific breakthrough conducted at Duke University School of Medicine, researchers have successfully demonstrated that early genetic and cellular markers of Alzheimer’s disease can be collected directly through a minimally invasive nasal swab.

The Duke Health team utilized an outpatient sampling procedure targeted at the high olfactory cleft to gather living mucosal neural tissue and immune cells without requiring surgical brain biopsies or invasive spinal taps.

As reported by Stephanie Lopez of Duke Health, Dr Bradley J. Goldstein, corresponding author and professor in the departments of Head and Neck Surgery & Communication Sciences at Duke University, stated:

“We want to be able to confirm Alzheimer’s very early, before damage has a chance to build up in the brain.”

As reported by Duke Health, medical student and study first author Vincent M. D’Anniballe noted:

“Much of what we know about Alzheimer’s comes from autopsy tissue. Now we can study living neural tissue, opening new possibilities for diagnosis and treatment.”

The researchers achieved an 81 per cent success rate in accurately differentiating early and clinical Alzheimer’s cases from healthy individuals by evaluating gene expressional profiles from the harvested nasal tissue.

What is the background of olfactory research in Alzheimer’s disease?

For several decades, clinical neurologists have observed that patients diagnosed with advanced Alzheimer’s disease frequently report a loss of smell or an inability to distinguish subtle scents. Historically, olfactory loss was regarded as an secondary symptom that emerged late in the pathology alongside broader cerebral atrophy.

However, initial post-mortem examinations consistently revealed high concentrations of neurofibrillary tangles and amyloid plaques within the olfactory bulb and entorhinal cortex. This prompted medical researchers to investigate whether the nasal-brain axis serves as an initial entry portal or an early indicator for systemic neurodegeneration.

With recent advancements in single-cell RNA sequencing and high-resolution brain imaging, medical research teams have successfully shifted their focus from late-stage autopsies to early-stage cellular monitoring in living subjects.

What is the prediction for how this development affects patients and medical practice?

This scientific development is predicted to transform clinical workflows for aging populations, individuals with a family history of dementia, and primary care physicians.

• For Patients and High-Risk Individuals: Patients who notice subtle changes in their sense of smell may soon have access to rapid, non-invasive outpatient screening methods. Early detection years before cognitive decline enables individuals to adopt preventative lifestyle modifications and seek early pharmacological treatments.
• For Clinicians and Neurologists: Medical professionals will gain a practical diagnostic tool that reduces reliance on expensive PET scans or lumbar punctures. Nasal swabs could serve as routine screening checks during annual physical examinations for older adults.
• For Pharmaceutical Developers: Drug manufacturers conducting clinical trials for disease-modifying therapies (such as monoclonal anti-amyloid antibodies) will be able to enroll patients at an earlier stage of disease progression, significantly improving therapeutic trial efficacy.